Zymedi Overview
- Year Founded
-
2019

- Status
-
Private
- Employees
-
27

- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$15M
- Investors
-
8
Zymedi General Information
Description
Developer of novel therapeutics platform intended to improve the quality of life of people suffering from diseases. The company's platform focuses on aminoacyl-tRNA synthetases (ARSs), pulmonary arterial hypertension, and liver fibrosis, enabling patients to begin treatment more quickly, resulting in a better medical outcome.
Contact Information
Website
www.zymedi.comCorporate Office
- Posco Green Building (Building 511)
- 85 Songdokwahak-ro, Yeonsu-gu
- Incheon, 21983
- South Korea
Corporate Office
- Posco Green Building (Building 511)
- 85 Songdokwahak-ro, Yeonsu-gu
- Incheon, 21983
- South Korea
Zymedi Timeline
Zymedi Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Early Stage VC (Series A) | 30-May-2023 | $15M | Completed | Pre-Clinical Trials | ||
2. Early Stage VC (Series A) | 26-Mar-2021 | Completed | Pre-Clinical Trials | |||
1. Angel (individual) | 01-Oct-2020 | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Zymedi Patents
Zymedi Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-4261279-A1 | Novel fragmented crs peptide exhibiting immune enhancement activity, and use thereof | Pending | 10-Dec-2020 | ||
JP-2024526483-A | Novel crs fragment peptide having immune enhancing activity and use thereof | Pending | 10-Dec-2020 | ||
EP-4261279-A4 | Novel fragmented crs peptide exhibiting immune enhancement activity, and use thereof | Pending | 10-Dec-2020 | ||
JP-2022500051-A | An antibody that specifically binds to the n-terminal region of lysyl-trna synthase exposed in the outer cell membrane. | Active | 17-Sep-2018 | ||
AU-2019341266-A1 | Antibody for specifically binding to lysyl-trna synthetase n-terminal domain exposed to extracellular membrane | Active | 17-Sep-2018 | C07K16/40 |
Zymedi Signals
Zymedi Investors (8)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Atinum Investment | Venture Capital | Minority | ||
CKD Venture Capital | Corporate Venture Capital | Minority | ||
Korea Development Bank | Investment Bank | Minority | ||
Korea Venture Investment | Fund of Funds | Minority | ||
Medytox Venture Investment | Corporate Venture Capital | Minority |
Zymedi FAQs
-
When was Zymedi founded?
Zymedi was founded in 2019.
-
Where is Zymedi headquartered?
Zymedi is headquartered in Incheon, South Korea.
-
What is the size of Zymedi?
Zymedi has 27 total employees.
-
What industry is Zymedi in?
Zymedi’s primary industry is Drug Discovery.
-
Is Zymedi a private or public company?
Zymedi is a Private company.
-
What is Zymedi’s current revenue?
The current revenue for Zymedi is
. -
How much funding has Zymedi raised over time?
Zymedi has raised $31.8M.
-
Who are Zymedi’s investors?
Atinum Investment, CKD Venture Capital, Korea Development Bank, Korea Venture Investment, and Medytox Venture Investment are 5 of 8 investors who have invested in Zymedi.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »